TMCnet News
BUYINS.NET: Market Maker Surveillance Report. CICI, EPGL, WEN, PFE, GE, AVNR, Highest Net Buy Volume With Lowest Price Friction For Monday, September 15th 2014(M2 PressWIRE Via Acquire Media NewsEdge) BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4654 companies with "abnormal" market making, 1512 companies with positive Friction Factors and 3686 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Monday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Communication Intelligence Corp (OTC:CICI), EP GLOBAL COMMUNICATIONS INC (OTC:EPGL), Wendy's Company (NASDAQ:WEN), Pfizer Inc (NYSE:PFE), General Electric Co (NYSE:GE), Avanir Pharmaceuticals Inc (NASDAQ:AVNR). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . Market Maker Friction Factor is shown in the chart below: Symbol Change Percent Buy Volume Buy %% Sell Volume Sell %% Net Volume Friction CICI $0.013 42.17% 2,272,549 85.49% 385,655 14.51% 1,886,894 1,429,465 EPGL $0.013 20.97% 1,827,959 78.85% 490,117 21.14% 1,337,842 1,029,109 WEN $0.090 1.14% 4,487,072 59.96% 2,972,879 39.73% 1,514,193 168,244 PFE $0.490 1.66% 8,660,942 35.70% 6,415,030 26.45% 2,245,912 45,835 GE $0.050 0.19% 6,160,561 40.17% 3,864,065 25.20% 2,296,496 459,299 AVNR $5.810 86.20% 45,657,105 51.47% 41,599,542 46.90% 4,057,563 6,984 Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar gains (Change) and very low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent. For example, the chart above shows CICI with a Net Buy Volume of 1,886,894 shares and a Friction Factor of 1,429,465 shares. That means that it takes 1,429,465 more shares of buying than selling to move CICI higher by one penny. This means the Market Makers are allowing the stock to move up higher as of Monday (lower friction). And with one of the highest Net Buy Volumes, the combination of low friction and high net buy volume is bullish. Communication Intelligence Corp (OTC:CICI) - Communication Intelligence Corporation supplies electronic signature solutions for business process automation. It offers enterprise-class SignatureOne and iSign suite of electronic signature solutions in software-as-a-service and on-premise delivery models for businesses to implement paperless electronic signature-driven business processes. The company s products include SignatureOne Ceremony Server to facilitate end-to-end management of multi-party approvals for PDF and XHTML documents; and iSign Console that allows users to upload documents for signature, select signers, and signature methods, as well as manages and enforces document workflow for routing, reviewing, signing, and notifications. Its products also comprise iSign suite, which consists of iSign mobile for signing on iOS and Android mobile devices; iSign forms for integrated use of templates and forms; and iSign live for simultaneous browsing signature ceremonies. In addition, the company offers Sign-it, a family of desktop software products that enable the real-time capture of electronic and digital signatures, as well as their verification and binding within applications; iSign toolkits, a suite of application development tools for electronic signature capture, encryption, and verification in custom applications and Web-based processes; and post-contract support, and upgrades or enhancement services. It serves channel partners, resellers, and end-user customers in the financial services industry primarily in North America, the ASEAN region, and Europe. The company was founded in 1981 and is headquartered in Redwood Shores, California.. EP GLOBAL COMMUNICATIONS INC (OTC:EPGL) - EP Global Communications, Inc. manufactures and markets medical devices. The company offers muscle pain detection device (MPPD), a medical device for both diagnosis and treatment of chronic back pain. It was formerly known as East Coast Airlines, Inc. and changed its name to EP Global Communications, Inc. in May 2000. EP Global Communications, Inc. was founded in 1999 and is based in Irvine, California.. Wendy's Company (NASDAQ:WEN) - The Wendy s Company, through its subsidiaries, owns and franchises Wendy s restaurant system. It engages in operating, developing, and franchising a system of distinctive quick-service restaurants. The company s restaurants specialize in offering hamburger sandwiches and featuring filet of chicken breast sandwiches; salads, soft drinks, Frosty desserts, and kids meals; and various promotional products on a limited time basis. As of December 29, 2013, it had 6,558 franchised and company-operated restaurants, including 6,158 in North America and 400 internationally. The company was formerly known as Wendy s/Arby s Group, Inc. and changed its name to The Wendy s Company in July 2011. The Wendy s Company was founded in 1969 and is headquartered in Dublin, Ohio.. Pfizer Inc (NYSE:PFE) - Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care physicians for Alzheimer s disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation therapeutic and disease areas. The company's Specialty Care and Oncology segment provides human prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. Its Established Products and Emerging Markets segment offers human prescription pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions, as well as that are sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. The company's Animal Health segment offers products and services to prevent and treat disease in livestock and companion animals, including anti-infectives, vaccines, parasiticides, medicinal feed additives, other pharmaceutical products, and other non-pharmaceutical products. Its Consumer Healthcare segment provides non-prescription products in therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. has a strategic collaboration with CytomX Therapeutics, Inc. to develop and commercialize Multiple Probody drug conjugates in oncology. The company was founded in 1849 and is headquartered in New York, New York.. General Electric Co (NYSE:GE) - General Electric Company operates as an infrastructure and financial services company worldwide. The company s Power and Water segment offers gas, steam and aeroderivative turbines, generators, combined cycle systems, controls, and related services; wind turbines and solar technology; and water treatment services and equipment. Its Oil and Gas segment provides surface and subsea drilling and production systems, equipment for floating production platforms, compressors, turbines, turboexpanders, reactors, industrial power generation, and auxiliary equipment. The company s Energy Management segments offers electrical distribution and control products, lighting and power panels, switchgears, and circuit breakers; engineering, inspection, mechanical, and emergency services; motors, drives, and control technologies; and plant automation, hardware, software, and embedded computing systems. Its Aviation segment offers jet engines, turboprop and turbo shaft engines, related replacement parts, and aerospace systems and equipment for military and commercial aircrafts; and maintenance, component repair, and overhaul services. The company s Healthcare segment provides medical imaging and information technologies, medical diagnostics, and patient monitoring systems; and disease research, drug discovery, and remote diagnostic and repair services. Its Transportation segment offers freight and passenger locomotives, diesel engines for rail, marine, and stationary power applications; railway signaling and communications systems; underground mining equipment; motorized drive systems; energy storage systems; and information technology solutions. Its Home and Business Solutions segment manufactures home appliances and lighting products. Its GE Capital segment offers commercial loans and leases, fleet management, financial programs, home loans, credit cards, personal loans, and other financial services. The company was founded in 1892 and is headquartered in Fairfield, Connecticut.. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) - Avanir Pharmaceuticals, Inc., together with its subsidiaries, is engaged in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. It primarily offers NUEDEXTA, a dual N-methyl-D-aspartate receptor antagonist and sigma-1 agonist for the treatment of pseudobulbar affect; and Docosanol 10% cream, an over-the-counter product for the treatment of cold sores. The company s clinical development stage products comprise AVP-923, which has completed Phase II clinical trials for the treatment of central neuropathic pain in patients with multiple sclerosis; is in Phase II clinical trials for the treatment of agitation in patients with Alzheimer s disease; and is in Phase II clinical trials for the treatment of levodopa-induced-dyskinesia in Parkinson s disease, as well as completed Phase III trials for the treatment of patients with diabetic peripheral neuropathic pain. It is also developing AVP-786, a Phase I clinical trial novel investigational drug product for the treatment of neurologic and psychiatric disorders; and AVP-825, an investigational drug-device combination product, which is in Phase III clinical trials, to treat acute migraine. The company has a license agreement with Concert Pharmaceuticals, Inc. to develop and commercialize deuterium-modified dextromethorphan for the potential treatment of neurologic and psychiatric disorders, as well as rights to other deuterium-modified dextromethorphan compounds; and a license agreement with OptiNose AS for the development and commercialization of a novel breath powered intranasal delivery system to treat acute migraine. Avanir Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.. About BUYINS.NET BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include: REGULATORY & COMPLIANCE NEWS Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO INVESTMENTS & TRADING SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports. Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks. Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups. Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks. GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time. DISCLAIMER: BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures. Contact: BUYINS.NET Thomas Ronk 800-715-9999800-715-9999 [email protected] www.buyins.netCallSend SMSAdd to SkypeYou'll need Skype CreditFree via Skype CONTACT: Buyins.net Thomas Ronk [email protected] www.buyins.net . (c) 2014 M2 COMMUNICATIONS |